According to the lawsuit, Sanofi has failed to provide partner Regeneron adequate information regarding the sales of Dupixent ...
Cendakimab fell short of the bar. The antibody hits IL-13, one of the interleukins targeted by Regeneron and Sanofi’s ...
A type of aggressive, treatment-resistant brain tumor has a distinct population of immune cells that support its growth, according to new research.
Evaluate’s latest analysis forecasts an $82 billion increase in major product revenues in 2025 – the largest annual growth ...
Sanofi in partnership with Regeneron to present 24 abstracts across approved and investigational medicines at AAAAI Annual Meeting in San Diego: Paris Friday, February 7, 2025, 12 ...
A type of aggressive, treatment-resistant brain tumor has a distinct population of immune cells that support its growth, ...
Learn more about whether Lantheus Holdings, Inc. or QuidelOrtho Corporation is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.
Hosted on MSN12h
The Best Scholarships For STEM MajorsThe cost of college continues to soar each year. Over the last 30 years, this cost has increased by up to to 500% — ...
The pharmaceutical giant named Jeffrey Legos the head of a division it is counting on to overcome investor pressure and grow ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback